IDH.L Regulatory News (IDH)

25 July 2011

Immunodiagnostic Systems Holdings plc

("IDS" or "the Company")

Appointment of Anthony Martin as Non-Executive Chairman

Immunodiagnostic Systems Holdings plc (AIM: IDH), a leading producer of specialist diagnostic testing kits for the clinical and research markets, announces the appointment of Dr Anthony Francis Martin as Non-Executive Chairman. The appointment will take effect on 8 September 2011. As announced at the preliminary results David Evans will stand down as Chairman at the AGM on 8 September 2011.

Anthony Martin has more than 25 years experience in life science and biotechnology businesses both in the UK and USA, in both executive and non-executive roles. He is currently Non-executive Chairman of Sphere Medical Holding plc, Wound Solutions Ltd and Phico Therapeutics Ltd.

Anthony has a Doctorate in Immunology from the University of Manchester Medical School and began his career in 1979 with Procter and Gamble before moving to Amersham International in Marketing and Business Development roles.

He has since run a number of biotechnology businesses including British Bio-Technology Products, AZUR Environmental, the Molecular Biology business of Invitrogen Corporation, and Molecular Probes Inc.

Previous Non-executive appointments include Prelude Trust plc, an investment trust that specialised in early stage, technology-based businesses and Chairman of NeuTec Pharma plc, a biopharmaceutical company he brought to the AIM market and subsequently sold to Novartis for £305million. Most recently he has served as Chairman of Molecular Insight Pharmaceuticals Inc., a NASDAQ quoted biopharmaceutical company specialising in new radiotherapies for heart disease and cancer. He has also served on the Boards of Invitrogen Corporation and Aligent Technologies.

Ian Cookson, Chief Executive Officer, Immunodiagnostic Systems Holdings plc, commented: "We are very pleased to announce the appointment of Anthony to the Board. Anthony has a very strong background in the biotechnology sector and his experience with investors in the United Kingdom and the United States will help the business to now make the transition to a substantially larger Company than it is today."

For further information:

Additional Information

Anthony Francis Martin, aged 57, holds no shares in the Company and other than as set out below there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Dr Martin's appointment as a Director of the Company.

Dr Martin is a director / partner or has been a director / partner of the following companies / partnerships during the previous five years: